Approval · Notice of Compliance 11998 · 2011
VIMOVO: Notice of Compliance 11998
Issued January 13, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11998
- Date
- January 13, 2011
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Therapeutic class
- Non steroidal anti-inflammatory drug (NSAID) / H+, K+-ATPase inhibitor
Products in this notice
Medicinal ingredients
- NAPROXEN 375 MG per TAB
- ESOMEPRAZOLE MAGNESIUM TRIHYDRATE 20 MG per TAB
- NAPROXEN 500 MG per TAB